News & Articles

The new division, led by Dr. Phil Jones, aims to offer a comprehensive drug discovery service to customers

Earlham Institute boosts national capability in genomics and single cell analysis with ultra-high throughput sequencing platform from Illumina

During the American Association for Cancer Research 2018 Annual Meeting, SelectScience recognized cutting-edge products and technologies advancing life sciences research

The trial demonstrates that first-line pembrolizumab treatment improved overall and progression-free survival rates in patients with metastatic nonsquamous non-small cell lung cancer

The primary endpoint for first-line nivolumab-ipilimumab combo trial indicates improved progression-free survival in patients with advanced non-small cell lung cancer

Expansion of circulating tumor-specific T cells after nivolumab treatment suggests systemic antitumor immunity in patients with resectable lung cancer

The FT819 CAR T cell line has the potential to be mass-produced, stored, and made readily available for cancer immunotherapy

Crizotinib yielded a high objective response rate for adult patients with ALK-positive Inflammatory myofibroblastic tumor, and a 100 percent disease control rate

New discoveries on devil facial tumor suggest that human cancer drugs may reduce the cancer mortality rate of Tasmanian devils - an endangered species naive to the Australian island of Tasmania

The HeraSafe 2030i BSC is designed to optimize contamination control and accelerate productivity across challenging cell culture applications

Team heading to Chicago, USA, to interview scientists at the forefront of cancer research and report on the newest technologies

Managing director believes the new Pharos V8 Instrument may revolutionize PCR techniques

Exciting new discovery describes the mechanism of action of a new class of antibiotics